GlobalData on MSN

FDA and EMA release collaborative AI framework for drug development

The joint guidance was created to ensure drug developers employ best practices when using AI.

DiMe introduces core digital measures set to accelerate drug development for pediatric rare diseases

The Digital Health Measurement Collaborative Community (DATAcc) by the Digital Medicine Society (DiMe) today announced the ...

Viking Therapeutics, Inc. (VKTX) advances obesity drug development and expands metabolic disease pipeline

Viking Therapeutics, Inc. (NASDAQ:VKTX) is one of the best US stocks to buy under $50. On January 12, Viking Therapeutics, ...

Scientists map a road to fairer, more inclusive drug development

A new analysis of drug trials used to approve medicines in the United States shows how far modern medicine still has to go to ...
Drug Target Review

Drug development in 2026: NAMs, safety and regulatory changes

Find out how NAMs are influencing safety assessments and decision-making in the pharmaceutical industry ahead of 2026.

From OpenAI’s offices to a deal with Eli Lilly — how Chai Discovery became one of the flashiest names in AI drug development

The startup has partnered with Eli Lilly and enjoys the backing of some of Silicon Valley's most influential VCs.

Ainnocence and Phase Advance Enter Industry-First AI Collab to Reduce Drug Development Timeline and Clinical Trial Risk

The collaboration marks a turning point in AI-driven drug design and trial forecasting, de-risking the drug development ...
The Scientist

Understanding the Drug Development Process

Developing high-quality, safe, and effective drugs is a complex process that requires varied scientific skills and stringent regulatory assessments. Drug development is a process that spans many years ...
The Next Web

Will AI revolutionise drug development? Researchers say it depends on how it’s used

Researchers have applied AI and machine learning to every stage of the drug development process. This includes identifying targets in the body, screening potential candidates, designing drug molecules ...
BioPharma Dive

BioMarin vets form Mendra to ‘modernize’ rare disease drug development

Backed with $82 million and led by two of BioMarin’s former executives, Mendra plans to acquire rare disease assets and use ...
PharmExec

Insilico Medicine Enters $120 Million Drug Development Collaboration with Qilu Pharmaceuticals to Advance Cardiometabolic Therapies

Insilico Medicine and Qilu Pharmaceutical Group announced a strategic collaboration to jointly develop small-molecule inhibitors for cardiometabolic diseases, combining Insilico’s generative AI–driven ...